A case of signet-ring cell carcinoma of the lung responding to S-1 as the third therapeutic regimen

Takako Hirota, Makoto Hamasaki, Taishi Harada, Masaki Fujita, Kazuki Nabeshima, Kentaro Watanabe

Research output: Contribution to journalArticle

Abstract

Background. Signet-ring cell carcinoma of the lung is a rare tumor with poor prognosis. No large-scale clinical trials have been published examining the effect of anticancer drugs. Case. A 38-year-old man was admitted to our hospital with an abnormal shadow in the right lung on a chest radiograph detected on a medical checkup. His right upper lobe was collapsed, and bronchial washing using a fiberoptic bronchoscope yielded a cytological diagnosis of adenocarcinoma. The right middle and lower lobes showed shadows suggestive of carcinomatous lymphangiosis, and metastatic lesions were identified in the cerebellar vermis. Because systemic anticancer chemotherapy consisting of docetaxel and cisplatin, and irinotecan and cisplatin did not have any effect S-1 was given as a third therapeutic regimen. A retroperitoneal metastatic mass adjacent to the left iliopsoas muscle and a right adrenal gland metastatic mass were transiently, but markedly reduced in size. Primary lung adenocarcinoma with signet-ring cell components was identified on autopsy. Conclusion. The effectiveness of S-1 should be considered which is an effective anticancer drug for gastric cancer, in the treatment of primary signet-ring cell carcinoma of the lung.

Original languageEnglish
Pages (from-to)287-291
Number of pages5
JournalJapanese Journal of Lung Cancer
Volume50
Issue number3
DOIs
Publication statusPublished - Jun 1 2010

Fingerprint

Signet Ring Cell Carcinoma
irinotecan
docetaxel
Lung
Cisplatin
Bronchoscopes
Cellular Structures
Adrenal Glands
Pharmaceutical Preparations
Stomach Neoplasms
Autopsy
Neoplasms
Adenocarcinoma
Thorax
Therapeutics
Clinical Trials
Drug Therapy
Muscles

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

A case of signet-ring cell carcinoma of the lung responding to S-1 as the third therapeutic regimen. / Hirota, Takako; Hamasaki, Makoto; Harada, Taishi; Fujita, Masaki; Nabeshima, Kazuki; Watanabe, Kentaro.

In: Japanese Journal of Lung Cancer, Vol. 50, No. 3, 01.06.2010, p. 287-291.

Research output: Contribution to journalArticle

Hirota, T, Hamasaki, M, Harada, T, Fujita, M, Nabeshima, K & Watanabe, K 2010, 'A case of signet-ring cell carcinoma of the lung responding to S-1 as the third therapeutic regimen', Japanese Journal of Lung Cancer, vol. 50, no. 3, pp. 287-291. https://doi.org/10.2482/haigan.50.287
Hirota, Takako ; Hamasaki, Makoto ; Harada, Taishi ; Fujita, Masaki ; Nabeshima, Kazuki ; Watanabe, Kentaro. / A case of signet-ring cell carcinoma of the lung responding to S-1 as the third therapeutic regimen. In: Japanese Journal of Lung Cancer. 2010 ; Vol. 50, No. 3. pp. 287-291.
@article{b5aa904959834eb6a46e4178ce18d4c2,
title = "A case of signet-ring cell carcinoma of the lung responding to S-1 as the third therapeutic regimen",
abstract = "Background. Signet-ring cell carcinoma of the lung is a rare tumor with poor prognosis. No large-scale clinical trials have been published examining the effect of anticancer drugs. Case. A 38-year-old man was admitted to our hospital with an abnormal shadow in the right lung on a chest radiograph detected on a medical checkup. His right upper lobe was collapsed, and bronchial washing using a fiberoptic bronchoscope yielded a cytological diagnosis of adenocarcinoma. The right middle and lower lobes showed shadows suggestive of carcinomatous lymphangiosis, and metastatic lesions were identified in the cerebellar vermis. Because systemic anticancer chemotherapy consisting of docetaxel and cisplatin, and irinotecan and cisplatin did not have any effect S-1 was given as a third therapeutic regimen. A retroperitoneal metastatic mass adjacent to the left iliopsoas muscle and a right adrenal gland metastatic mass were transiently, but markedly reduced in size. Primary lung adenocarcinoma with signet-ring cell components was identified on autopsy. Conclusion. The effectiveness of S-1 should be considered which is an effective anticancer drug for gastric cancer, in the treatment of primary signet-ring cell carcinoma of the lung.",
author = "Takako Hirota and Makoto Hamasaki and Taishi Harada and Masaki Fujita and Kazuki Nabeshima and Kentaro Watanabe",
year = "2010",
month = "6",
day = "1",
doi = "10.2482/haigan.50.287",
language = "English",
volume = "50",
pages = "287--291",
journal = "Japanese Journal of Lung Cancer",
issn = "0386-9628",
publisher = "Japan Lung Cancer Society",
number = "3",

}

TY - JOUR

T1 - A case of signet-ring cell carcinoma of the lung responding to S-1 as the third therapeutic regimen

AU - Hirota, Takako

AU - Hamasaki, Makoto

AU - Harada, Taishi

AU - Fujita, Masaki

AU - Nabeshima, Kazuki

AU - Watanabe, Kentaro

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Background. Signet-ring cell carcinoma of the lung is a rare tumor with poor prognosis. No large-scale clinical trials have been published examining the effect of anticancer drugs. Case. A 38-year-old man was admitted to our hospital with an abnormal shadow in the right lung on a chest radiograph detected on a medical checkup. His right upper lobe was collapsed, and bronchial washing using a fiberoptic bronchoscope yielded a cytological diagnosis of adenocarcinoma. The right middle and lower lobes showed shadows suggestive of carcinomatous lymphangiosis, and metastatic lesions were identified in the cerebellar vermis. Because systemic anticancer chemotherapy consisting of docetaxel and cisplatin, and irinotecan and cisplatin did not have any effect S-1 was given as a third therapeutic regimen. A retroperitoneal metastatic mass adjacent to the left iliopsoas muscle and a right adrenal gland metastatic mass were transiently, but markedly reduced in size. Primary lung adenocarcinoma with signet-ring cell components was identified on autopsy. Conclusion. The effectiveness of S-1 should be considered which is an effective anticancer drug for gastric cancer, in the treatment of primary signet-ring cell carcinoma of the lung.

AB - Background. Signet-ring cell carcinoma of the lung is a rare tumor with poor prognosis. No large-scale clinical trials have been published examining the effect of anticancer drugs. Case. A 38-year-old man was admitted to our hospital with an abnormal shadow in the right lung on a chest radiograph detected on a medical checkup. His right upper lobe was collapsed, and bronchial washing using a fiberoptic bronchoscope yielded a cytological diagnosis of adenocarcinoma. The right middle and lower lobes showed shadows suggestive of carcinomatous lymphangiosis, and metastatic lesions were identified in the cerebellar vermis. Because systemic anticancer chemotherapy consisting of docetaxel and cisplatin, and irinotecan and cisplatin did not have any effect S-1 was given as a third therapeutic regimen. A retroperitoneal metastatic mass adjacent to the left iliopsoas muscle and a right adrenal gland metastatic mass were transiently, but markedly reduced in size. Primary lung adenocarcinoma with signet-ring cell components was identified on autopsy. Conclusion. The effectiveness of S-1 should be considered which is an effective anticancer drug for gastric cancer, in the treatment of primary signet-ring cell carcinoma of the lung.

UR - http://www.scopus.com/inward/record.url?scp=77955790906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955790906&partnerID=8YFLogxK

U2 - 10.2482/haigan.50.287

DO - 10.2482/haigan.50.287

M3 - Article

VL - 50

SP - 287

EP - 291

JO - Japanese Journal of Lung Cancer

JF - Japanese Journal of Lung Cancer

SN - 0386-9628

IS - 3

ER -